Skip to main content
Top
Published in: Digestive Diseases and Sciences 4/2020

01-04-2020 | Chronic Inflammatory Bowel Disease | Stanford Multidisciplinary Seminars

Double Threat: Interplay of Celiac Disease with Inflammatory Bowel Disease

Authors: John Gubatan, George Triadafilopoulos, Nielsen Q. Fernandez-Becker

Published in: Digestive Diseases and Sciences | Issue 4/2020

Login to get access

Excerpt

A 54-year-old woman with a history of depression, obsessive–compulsive disorder, and urinary urge incontinence was initially evaluated in the gastroenterology clinic with complaints of explosive diarrhea, fecal urgency, rectal bleeding, and a 60-lbs unintentional weight loss over the previous year. She reported chronic diarrhea for over 40 years. A previous flexible sigmoidoscopy had revealed proctitis; at that point, she was managed on mesalamine suppositories but continued with intermittent symptoms. About 7 years prior to presentation, she underwent an esophagogastroduodenoscopy (EGD) that demonstrated an endoscopically normal-appearing duodenum; duodenal biopsies revealed increased intraepithelial lymphocytes with mild focal villous blunting concerning for celiac disease. Colonoscopy with random colonic biopsies revealed no evidence of colitis. She was placed on a gluten-free diet (GFD) for 6 months, but this was discontinued due to lack of efficacy. She continued to have ongoing symptoms while not consuming a gluten-free diet (GFD). Laboratory studies were notable for elevated anti-gliadin IgA (> 100), but otherwise the absence of HLA-DQ2/DQ8 alleles and a negative endomysial antibody. She was restarted on a GFD, but the patient was not compliant. …
Literature
1.
go back to reference Pascual V, Dieli-Crimi R, López-Palacios N, Bodas A, Medrano LM, Núñez C. Inflammatory bowel disease and celiac disease: overlaps and differences. World J Gastroenterol WJG. 2014;20:4846.CrossRef Pascual V, Dieli-Crimi R, López-Palacios N, Bodas A, Medrano LM, Núñez C. Inflammatory bowel disease and celiac disease: overlaps and differences. World J Gastroenterol WJG. 2014;20:4846.CrossRef
2.
go back to reference De Souza HS, Fiocchi C, Iliopoulos D. The IBD interactome: an integrated view of aetiology, pathogenesis and therapy. Nat Rev Gastroenterol Hepatol. 2017;14:739.CrossRef De Souza HS, Fiocchi C, Iliopoulos D. The IBD interactome: an integrated view of aetiology, pathogenesis and therapy. Nat Rev Gastroenterol Hepatol. 2017;14:739.CrossRef
3.
go back to reference Megiorni F, Mora B, Bonamico M, et al. HLA-DQ and risk gradient for celiac disease. Hum Immunol. 2009;70:55–59.CrossRef Megiorni F, Mora B, Bonamico M, et al. HLA-DQ and risk gradient for celiac disease. Hum Immunol. 2009;70:55–59.CrossRef
4.
go back to reference Karell K, Louka AS, Moodie SJ, et al. HLA types in celiac disease patients not carrying the DQA1* 05-DQB1* 02 (DQ2) heterodimer: results from the European Genetics Cluster on Celiac Disease. Hum Immunol. 2003;64:469–477.CrossRef Karell K, Louka AS, Moodie SJ, et al. HLA types in celiac disease patients not carrying the DQA1* 05-DQB1* 02 (DQ2) heterodimer: results from the European Genetics Cluster on Celiac Disease. Hum Immunol. 2003;64:469–477.CrossRef
5.
go back to reference Shah A, Walker M, Burger D, et al. Link between celiac disease and inflammatory bowel disease. J Clin Gastroenterol. 2019;53:514–522.CrossRef Shah A, Walker M, Burger D, et al. Link between celiac disease and inflammatory bowel disease. J Clin Gastroenterol. 2019;53:514–522.CrossRef
6.
go back to reference Tse CS, Deepak P, De La Fuente J, et al. Phenotype and clinical course of inflammatory bowel disease with co-existent celiac disease. J Crohn’s Colitis. 2018;12:973–980.CrossRef Tse CS, Deepak P, De La Fuente J, et al. Phenotype and clinical course of inflammatory bowel disease with co-existent celiac disease. J Crohn’s Colitis. 2018;12:973–980.CrossRef
7.
go back to reference Glas J, Stallhofer J, Ripke S, et al. Novel genetic risk markers for ulcerative colitis in the IL2/IL21 region are in epistasis with IL23R and suggest a common genetic background for ulcerative colitis and celiac disease. Am J Gastroenterol. 2009;104:1737.CrossRef Glas J, Stallhofer J, Ripke S, et al. Novel genetic risk markers for ulcerative colitis in the IL2/IL21 region are in epistasis with IL23R and suggest a common genetic background for ulcerative colitis and celiac disease. Am J Gastroenterol. 2009;104:1737.CrossRef
8.
go back to reference Fina D, Sarra M, Caruso R, et al. Interleukin 21 contributes to the mucosal T helper cell type 1 response in coeliac disease. Gut. 2008;57:887–892.CrossRef Fina D, Sarra M, Caruso R, et al. Interleukin 21 contributes to the mucosal T helper cell type 1 response in coeliac disease. Gut. 2008;57:887–892.CrossRef
9.
go back to reference Gubatan J, Moss AC. Vitamin D in inflammatory bowel disease: more than just a supplement. Curr Opin Gastroenterol. 2018;34:217–225.CrossRef Gubatan J, Moss AC. Vitamin D in inflammatory bowel disease: more than just a supplement. Curr Opin Gastroenterol. 2018;34:217–225.CrossRef
10.
go back to reference Gubatan J, Mitsuhashi S, Zenlea T, Rosenberg L, Robson S, Moss AC. Low serum vitamin D during remission increases risk of clinical relapse in patients with ulcerative colitis. Clin Gastroenterol Hepatol. 2017;15:240.CrossRef Gubatan J, Mitsuhashi S, Zenlea T, Rosenberg L, Robson S, Moss AC. Low serum vitamin D during remission increases risk of clinical relapse in patients with ulcerative colitis. Clin Gastroenterol Hepatol. 2017;15:240.CrossRef
Metadata
Title
Double Threat: Interplay of Celiac Disease with Inflammatory Bowel Disease
Authors
John Gubatan
George Triadafilopoulos
Nielsen Q. Fernandez-Becker
Publication date
01-04-2020
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 4/2020
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-019-05994-9

Other articles of this Issue 4/2020

Digestive Diseases and Sciences 4/2020 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.